2020 Volume 34 Issue 5 Pages 890-896
Lanreotide is a long acting somatostatin analogue and gallstones are reported in over 5% as a side effect. But there are no previous treated reports of patients for biliary tract stones during lanreotide therapy. We herein report a treatment case of gallbladder and common bile duct stones during lanreotide therapy. A 74-year-old female was diagnosed with a pituitary adenoma and acromegaly in 1985. After two times operations and stereotactic radioterapy, octreotide was started in 2000, and lanreotide given since 2014. In 2018, abdominal pain began after colonoscopy and a splenic hematoma suspected on abdominal CT scan and admitted urgently. Laboratory check pointed out liver dysfunction and further evaluations revealed gallbladder and common bile duct stones. After removing the common bile duct stone endoscopically, laparoscopic cholecystectomy was performed. Componential analysis of stone revealed that the stones were calcium bilirubinate gallstones including over 98% calcium bilirubinate.
